Key points:
• Biology of Blood and Marrow Transplantation, the official publication of the American Society
for Transplantation and Cellular Therapy, publishes three peer-reviewed articles detailing
results from three separate trials of remestemcel-L in children and adults with acute graft
versus host disease
• Publications highlight consistent benefits seen across all three trials in patients with greatest
levels of inflammation and the most severe grades of the disease
• Trial results underpin Mesoblast’s Biologics License Application to seek approval of its product
candidate RYONCIL™ (remestemcel-L) for pediatric steroid-refractory acute graft versus host
disease (GVHD), which has been accepted for priority review by the United States Food and
Drug Administration (FDA)
• These outcomes also provide the rationale for use of remestemcel-L in other conditions
associated with severe inflammation and cytokine release, including COVID-19 infection
- Forums
- ASX - By Stock
- MSB
- Ann: 3 Articles on RYONCIL GvHD Trial Results Published in BBMT
Ann: 3 Articles on RYONCIL GvHD Trial Results Published in BBMT, page-8
-
- There are more pages in this discussion • 120 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.18 |
Change
0.015(1.29%) |
Mkt cap ! $1.347B |
Open | High | Low | Value | Volume |
$1.15 | $1.20 | $1.15 | $4.551M | 3.886M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 98246 | $1.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.18 | 19079 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 98246 | 1.170 |
3 | 57092 | 1.165 |
3 | 31212 | 1.160 |
3 | 31550 | 1.155 |
10 | 181451 | 1.150 |
Price($) | Vol. | No. |
---|---|---|
1.180 | 19079 | 2 |
1.185 | 7708 | 3 |
1.190 | 96412 | 6 |
1.195 | 54980 | 3 |
1.200 | 160164 | 15 |
Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |